Search

Your search keyword '"Clausen, Michael"' showing total 170 results
Start Over Author "Clausen, Michael" Search Limiters Peer Reviewed
170 results on '"Clausen, Michael"'

2. Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study

Author

Linton, Kim M, Vitolo, Umberto, Jurczak, Wojciech, Lugtenburg, Pieternella J, Gyan, Emmanuel, Sureda, Anna, Christensen, Jacob Haaber, Hess, Brian, Tilly, Hervé, Cordoba, Raul, Lewis, David John, Okada, Craig, Hutchings, Martin, Clausen, Michael Roost, Sancho, Juan-Manuel, Cochrane, Tara, Leppä, Sirpa, Chamuleau, Martine E D, Gernhardt, Diana, Altıntaş, Işıl, Liu, Yan, Ahmadi, Tahamtan, Dinh, Minh H, Hoehn, Daniela, Favaro, Elena, Elliott, Brian, Thieblemont, Catherine, and Vose, Julie M

Published
2024
Full Text
View/download PDF

6. Risk of diabetes and the impact on preexisting diabetes in patients with lymphoma treated with steroid-containing immunochemotherapy

Author

Baech, Joachim, Severinsen, Marianne Tang, Øvlisen, Andreas K., Frederiksen, Henrik, Vestergaard, Peter, Torp-Pedersen, Christian, Jørgensen, Judit, Clausen, Michael Roost, Poulsen, Christian B., Brown, Peter, Gang, Anne Ortved, Pedersen, Robert Schou, Ekström Smedby, Karin, Eloranta, Sandra, Jakobsen, Lasse Hjort, and El-Galaly, Tarec Christoffer

Published
2022
Full Text
View/download PDF

8. Effectiveness of R‐CHOP versus R‐CHOEP for treatment of young patients with high‐risk diffuse large B‐cell lymphoma: A Danish observational population‐based study.

Author

Rask Kragh Jørgensen, Rasmus, Jakobsen, Lasse Hjort, Eloranta, Sandra, Smedby, Karin E., Pedersen, Robert Schou, Jørgensen, Judit M., Clausen, Michael Roost, Brown, Peter, Gang, Anne Ortved, Gade, Inger‐Lise, Larsen, Thomas Stauffer, Jerkeman, Mats, and El‐Galaly, Tarec Christoffer

Subjects
CANCER treatment, GENETIC techniques, DIFFUSE large B-cell lymphomas, OVERALL survival, TREATMENT effectiveness
Abstract

Purpose: Etoposide to standard R‐CHOP is used for high‐risk diffuse large B‐cell lymphoma (DLBCL) in some countries. Due to the lack of randomized trials, a real‐world data study using matching methods was used to test the potential effectiveness of R‐CHOEP over R‐CHOP. Patients and Methods: This study included patients from the Danish Lymphoma Register diagnosed between 2006 and 2020 at the age of 18–60 years with de novo DLBCL and age‐adjusted IPI ≥2. R‐CHOEP treated patients were matched 1:1 without replacement to R‐CHOP treated patients using a hybrid exact and genetic matching technique. Primary endpoints were progression‐free survival (PFS) and overall survival (OS). Results: In total, 396 patients were included; 213 received R‐CHOEP and 183 received R‐CHOP. Unadjusted 5‐year PFS and OS for R‐CHOEP were 69% (95% Confidence intervals [CI]; 63%–76%) and 79% (CI;73%–85%) versus 62% (CI;55%–70%) and 76% (CI;69%–82%) for R‐CHOP (log‐rank test, PFS p =.25 and OS p =.31). A total of 127 patients treated with R‐CHOEP were matched to 127 patients treated with R‐CHOP. Matching‐adjusted 5‐year PFS and OS were 65% (CI; 57%–74%) and 79% (CI; 72%–84%) for R‐CHOEP versus 63% (CI; 55%–73%) and 79% (CI;72%–87%) for R‐CHOP (log‐rank test, PFS p =.90 and OS p =.63). Conclusion: The present study did not confirm superiority of R‐CHOEP over R‐CHOP for young patients with high‐risk DLBCL. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

9. Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study

Author

Hutchings, Martin, Mous, Rogier, Clausen, Michael Roost, Johnson, Peter, Linton, Kim M, Chamuleau, Martine E D, Lewis, David John, Sureda Balari, Anna, Cunningham, David, Oliveri, Roberto S, Elliott, Brian, DeMarco, Dena, Azaryan, Ada, Chiu, Christopher, Li, Tommy, Chen, Kuo-mei, Ahmadi, Tahamtan, and Lugtenburg, Pieternella J

Published
2021
Full Text
View/download PDF

10. Walnut Allergy Across Europe: Distribution of Allergen Sensitization Patterns and Prediction of Severity

Author

Lyons, Sarah A., Datema, Mareen R., Le, Thuy-My, Asero, Riccardo, Barreales, Laura, Belohlavkova, Simona, de Blay, Frédéric, Clausen, Michael, Dubakiene, Ruta, Fernández-Perez, Cristina, Fritsche, Philipp, Gislason, David, Hoffmann-Sommergruber, Karin, Jedrzejczak-Czechowicz, Monika, Jongejan, Laurian, Kowalski, Marek L., Kralimarkova, Tanya Z., Lidholm, Jonas, Papadopoulos, Nikolaos G., Pontoppidan, Bo, Popov, Todor A., Prado, Nayade del, Purohit, Ashok, Reig, Isabel, Seneviratne, Suranjith L., Sinaniotis, Athanasios, Vassilopoulou, Emilia, Versteeg, Serge A., Vieths, Stefan, Zwinderman, Aeilko H., Welsing, Paco M.J., Mills, E.N. Clare, Ballmer-Weber, Barbara K., Knulst, André C., Fernández-Rivas, Montserrat, and Van Ree, Ronald

Published
2021
Full Text
View/download PDF

11. The role of trephine bone marrow biopsies in the era of measurable residual disease—Results from the CLL10 trial of the German CLL Study Group (GCLLSG).

Author

Kutsch, Nadine, Robrecht, Sandra, Fink, Anna, Lange, Elisabeth, Weide, Rudolf, Kiehl, Michael G., Sökler, Martin, Schlag, Rudolf, Vehling‐Kaiser, Ursula, Köchling, Georg, Plöger, Christoph, Gregor, Michael, Plesner, Torben, Clausen, Michael R., Oschlies, Ilske, Ritgen, Matthias, Herling, Marco, Fischer, Kirsten, Döhner, Hartmut, and Wendtner, Clemens‐Martin

Published
2024
Full Text
View/download PDF

12. Revisiting beta‐2 microglobulin as a prognostic marker in diffuse large B‐cell lymphoma.

Author

Jelicic, Jelena, Juul‐Jensen, Karen, Bukumiric, Zoran, Runason Simonsen, Mikkel, Roost Clausen, Michael, Ludvigsen Al‐Mashhadi, Ahmed, Schou Pedersen, Robert, Bjørn Poulsen, Christian, Ortved Gang, Anne, Brown, Peter, El‐Galaly, Tarec Christoffer, and Larsen, Thomas Stauffer

Subjects
PROGNOSIS, DIFFUSE large B-cell lymphomas, DISEASE risk factors, OVERALL survival, PROGNOSTIC models
Abstract

Background: Several clinical prognostic models for diffuse large B‐cell lymphoma (DLBCL) have been proposed, including the most commonly used International Prognostic Index (IPI), the National Comprehensive Cancer Network IPI (NCCN‐IPI), and models incorporating beta‐2 microglobulin (β2M). However, the role of β2M in DLBCL patients is not fully understood. Methods: We identified 6075 patients with newly diagnosed DLBCL treated with immunochemotherapy registered in the Danish Lymphoma Registry. Results: A total of 3232 patients had data available to calculate risk scores from each of the nine considered risk models for DLBCL, including a model developed from our population. Three of four models with β2M and NCCN‐IPI performed better than the International Prognostic Indexes (IPI, age‐adjusted IPI, and revised IPI). Five‐year overall survival for high‐ and low‐risk patients were 43.6% and 86.4% for IPI and 34.9% and 96.2% for NCCN‐IPI. In univariate analysis, higher levels of β2M were associated with inferior survival, higher tumor burden (advanced clinical stage and bulky disease), previous malignancy and increased age, and creatinine levels. Furthermore, we developed a model (β2M‐NCCN‐IPI) by adding β2M to NCCN‐IPI (c‐index 0.708) with improved discriminatory ability compared to NCCN‐IPI (c‐index 0.698, p < 0.05) and 5‐year OS of 33.1%, 56.2%, 82.4%, and 96.4% in the high, high‐intermediate, low‐intermediate and low‐risk group, respectively. Conclusion: International Prognostic Indices, except for NCCN‐IPI, fail to accurately discriminate risk groups in the rituximab era. β2M, a readily available marker, could improve the discriminatory performance of NCCN‐IPI and should be re‐evaluated in the development setting of future models for DLBCL. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

13. Predictors of Food Sensitization in Children and Adults Across Europe

Author

Lyons, Sarah A., Knulst, André C., Burney, Peter G.J., Fernández-Rivas, Montserrat, Ballmer-Weber, Barbara K., Barreales, Laura, Bieli, Christian, Clausen, Michael, Dubakiene, Ruta, Fernández-Perez, Cristina, Jedrzejczak-Czechowicz, Monika, Kowalski, Marek L., Kummeling, Ischa, Mustakov, Tihomir B., van Os-Medendorp, Harmieke, Papadopoulos, Nikolaos G., Popov, Todor A., Potts, James, Xepapadaki, Paraskevi, Welsing, Paco M.J., Mills, E. N. Clare, van Ree, Ronald, and Le, Thuy-My

Published
2020
Full Text
View/download PDF

14. Prevalence of Food Sensitization and Food Allergy in Children Across Europe

Author

Lyons, Sarah A., Clausen, Michael, Knulst, André C., Ballmer-Weber, Barbara K., Fernandez-Rivas, Montserrat, Barreales, Laura, Bieli, Christian, Dubakiene, Ruta, Fernandez-Perez, Cristina, Jedrzejczak-Czechowicz, Monika, Kowalski, Marek L., Kralimarkova, Tanya, Kummeling, Ischa, Mustakov, Tihomir B., Papadopoulos, Nikolaos G., Popov, Todor A., Xepapadaki, Paraskevi, Welsing, Paco M.J., Potts, James, Mills, E.N. Clare, van Ree, Ronald, Burney, Peter G.J., and Le, Thuy-My

Published
2020
Full Text
View/download PDF

16. Risk Factors for Hen's Egg Allergy in Europe: EuroPrevall Birth Cohort

Author

Grimshaw, Kate E.C., Roberts, Graham, Selby, Anna, Reich, Andreas, Butiene, Indra, Clausen, Michael, Dubakiene, Ruta, Fiandor, Ana, Fiocchi, Alessandro, Grabenhenrich, Linus B., Larco, Jose Ignacio, Kowalski, Marek L., Rudzeviciene, Odilija, Papadopoulos, Nikolaos G., Rosenfeld, Leonard, Sigurdardottir, Sigurveig Th., Sprikkelman, Aline B., Schoemaker, Ana A., Xepapadaki, Paraskevi, Mills, E.N. Clare, Keil, Thomas, and Beyer, Kirsten

Published
2020
Full Text
View/download PDF

17. Patients in complete remission after R-CHOP(-like) therapy for diffuse large B-cell lymphoma have limited excess use of health care services in Denmark

Author

Jakobsen, Lasse Hjort, Øvlisen, Andreas Kiesbye, Severinsen, Marianne Tang, Bæch, Joachim, Kragholm, Kristian Hay, Glimelius, Ingrid, Gang, Anne Ortved, Jørgensen, Judit Mészáros, Frederiksen, Henrik, Poulsen, Christian Bjørn, Clausen, Michael Roost, Pedersen, Per Trøllund, Pedersen, Robert Schou, Torp-Pedersen, Christian, Eloranta, Sandra, and El-Galaly, Tarec Christoffer

Published
2022
Full Text
View/download PDF

18. Food Allergy in Adults: Substantial Variation in Prevalence and Causative Foods Across Europe

Author

Lyons, Sarah A., Burney, Peter G.J., Ballmer-Weber, Barbara K., Fernandez-Rivas, Montserrat, Barreales, Laura, Clausen, Michael, Dubakiene, Ruta, Fernandez-Perez, Cristina, Fritsche, Philipp, Jedrzejczak-Czechowicz, Monika, Kowalski, Marek L., Kralimarkova, Tanya, Kummeling, Ischa, Mustakov, Tihomir B., Lebens, Ans F.M., van Os-Medendorp, Harmieke, Papadopoulos, Nikolaos G., Popov, Todor A., Sakellariou, Alexandros, Welsing, Paco M.J., Potts, James, Mills, E.N. Clare, van Ree, Ronald, Knulst, André C., and Le, Thuy-My

Published
2019
Full Text
View/download PDF

19. Recommendations for asthma monitoring in children: A PeARL document endorsed by APAPARI, EAACI, INTERASMA, REG, and WAO.

Author

Papadopoulos, Nikolaos G., Custovic, Adnan, Deschildre, Antoine, Gern, James E., Nieto Garcia, Antonio, Miligkos, Michael, Phipatanakul, Wanda, Wong, Gary, Xepapadaki, Paraskevi, Agache, Ioana, Arasi, Stefania, Awad El‐Sayed, Zeinab, Bacharier, Leonard B., Bonini, Matteo, Braido, Fulvio, Caimmi, Davide, Castro‐Rodriguez, Jose A., Chen, Zhimin, Clausen, Michael, and Craig, Timothy

Subjects
ASTHMA in children, MEDICAL personnel, DELPHI method, PATIENT compliance, WELL-being, CELIAC disease, WHEEZE
Abstract

Monitoring is a major component of asthma management in children. Regular monitoring allows for diagnosis confirmation, treatment optimization, and natural history review. Numerous factors that may affect disease activity and patient well‐being need to be monitored: response and adherence to treatment, disease control, disease progression, comorbidities, quality of life, medication side‐effects, allergen and irritant exposures, diet and more. However, the prioritization of such factors and the selection of relevant assessment tools is an unmet need. Furthermore, rapidly developing technologies promise new opportunities for closer, or even "real‐time," monitoring between visits. Following an approach that included needs assessment, evidence appraisal, and Delphi consensus, the PeARL Think Tank, in collaboration with major international professional and patient organizations, has developed a set of 24 recommendations on pediatric asthma monitoring, to support healthcare professionals in decision‐making and care pathway design. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

20. Real‐world outcomes following third or subsequent lines of therapy: A Danish population‐based study on 189 patients with relapsed/refractory large B‐cell lymphomas.

Author

AL‐Mashhadi, Ahmed Ludvigsen, Jakobsen, Lasse Hjort, Brown, Peter, Gang, Anne Ortved, Thorsteinsson, Anne‐Luise, Rasoul, Kaziwa, Haissman, Judith Melchior, Tøstesen, Michael Buch, Christoffersen, Mette Niemann, Jelicic, Jelena, Jørgensen, Jennifer Bøgh, Thomsen, Troels, Dessau‐Arp, Andriette, Andersen, Andreas P. H., Frederiksen, Mikael, Pedersen, Per Trøllund, Clausen, Michael Roost, Jørgensen, Judit Meszaros, Poulsen, Christian Bjørn, and El‐Galaly, Tarec Christoffer

Subjects
RITUXIMAB, DIFFUSE large B-cell lymphomas, LYMPHOMAS, DISEASE risk factors, SALVAGE therapy, DANES
Abstract

Summary: Outcome data of patients with relapsed/refractory (R/R) diffuse large B‐cell lymphoma (DLBCL) beyond the second line are scarce outside of clinical trials. Novel therapies in the R/R setting have been approved based on single‐arm trials, but results need to be contextualized by real‐world outcomes. Medical records from 3753 Danish adults diagnosed with DLBCL were reviewed. Patients previously treated with rituximab and anthracycline‐based chemotherapy who received the third or later line (3 L+) of treatment after 1 January 2015, were included. Only 189 patients with a median age of 71 years were eligible. The median time since the last line of therapy was 6 months. Patients were treated with either best supportive care (22%), platinum‐based salvage therapy (13%), low‐intensity chemotherapy (22%), in clinical trial (14%) or various combination treatments (32%). The 2‐year OS‐/PFS estimates were 25% and 12% for all patients and 49% and 17% for those treated with platinum‐based salvage therapy. Age ≥70, CNS involvement, elevated LDH and ECOG ≥2 predicted poor outcomes, and patients with 0–1 of these risk factors had a 2‐year OS estimate of 65%. Only a very small fraction of DLBCL patients received third‐line treatment and were eligible for inclusion. Outcomes were generally poor, but better in intensively treated, fit young patients with limited disease. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

22. ABCL-422 Subcutaneous Epcoritamab in Patients With Relapsed or Refractory Large B-Cell Lymphoma (EPCORE NHL-1): Pivotal Results from a Phase 2 Study

Author

Thieblemont, Catherine, Phillips, Tycel, Ghesquieres, Herve, Cheah, Chan Y., Clausen, Michael Roost, Cunningham, David, Do, Young Rok, Feldman, Tatyana, Gasiorowski, Robin, Jurczak, Wojciech, Kim, Tae Min, Lewis, David John, van der Poel, Marjolein, Poon, Michelle Limei, Doerr, Thomas, Kilavuz, Nurgul, Chen, Menghui, Sacchi, Mariana, Elliott, Brian, Hutchings, Martin, and Lugtenburg, Pieternella

Published
2022
Full Text
View/download PDF

23. Treatment strategies and outcomes in diffuse large B-cell lymphoma among 1011 patients aged 75 years or older: A Danish population-based cohort study

Author

Juul, Maja Bech, Jensen, Pernille Hammershoej, Engberg, Henriette, Wehberg, Sonja, Dessau-Arp, Andriette, Haziri, Donika, Kristensen, Helene Bjoerg, Baech, Joachim, Schurmann, Lene, Clausen, Michael Roost, Valentin, Rebecca, Knudsen, Lene Meldgaard, Munksgaard, Lars, El-Galaly, Tarec Christoffer, Frederiksen, Henrik, and Larsen, Thomas Stauffer

Published
2018
Full Text
View/download PDF

24. Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma

Author

El-Galaly, Tarec Christoffer, Cheah, Chan Yoon, Bendtsen, Mette Dahl, Nowakowski, Grzegorz S., Kansara, Roopesh, Savage, Kerry J., Connors, Joseph M., Sehn, Laurie H., Goldschmidt, Neta, Shaulov, Adir, Farooq, Umar, Link, Brian K., Ferreri, Andrés J.M., Calimeri, Teresa, Cecchetti, Caterina, Dann, Eldad J., Thompson, Carrie A., Inbar, Tsofia, Maurer, Matthew J., Gade, Inger Lise, Juul, Maja Bech, Hansen, Jakob W., Holmberg, Staffan, Larsen, Thomas S., Cordua, Sabrina, Mikhaeel, N. George, Hutchings, Martin, Seymour, John F., Clausen, Michael Roost, Smith, Daniel, Opat, Stephen, Gilbertson, Michael, Thanarajasingam, Gita, and Villa, Diego

Published
2018
Full Text
View/download PDF

26. The number of extranodal sites assessed by PET/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B-cell lymphoma: An international multicenter study of 1532 patients treated with chemoimmunotherapy

Author

El-Galaly, Tarec Christoffer, Villa, Diego, Michaelsen, Thomas Yssing, Hutchings, Martin, Mikhaeel, Nabegh George, Savage, Kerry J., Sehn, Laurie H., Barrington, Sally, Hansen, Jakob W., Smith, Daniel, Rady, Kirsty, Mylam, Karen J., Larsen, Thomas S., Holmberg, Staffan, Juul, Maja B., Cordua, Sabrina, Clausen, Michael R., Jensen, Kristina B., Johnsen, Hans E., Seymour, John F., Connors, Joseph M., de Nully Brown, Peter, Bøgsted, Martin, and Cheah, Chan Y.

Published
2017
Full Text
View/download PDF

27. Low mortality from COVID‐19 infection in patients with B‐cell lymphoma after bispecific CD20xCD3 therapy.

Author

Kyvsgaard, Emil R., Riley, Caroline, Clausen, Michael Roost, Harsløf, Mads, Heftdal, Line Dam, Niemann, Carsten U., Grønbæk, Kirsten, Hutchings, Martin, and Husby, Simon

Subjects
SARS-CoV-2, COVID-19, COUGH
Abstract

A study published in the British Journal of Haematology examined the impact of COVID-19 on patients with B-cell non-Hodgkin lymphoma (B-NHL) who received bispecific antibodies. The study included 130 Danish patients who were treated with glofitamab or epcoritamab. Of the 43 patients who were infected with COVID-19, the majority were in complete remission at the time of diagnosis. The severity of COVID-19 symptoms varied, with 2 patients experiencing critical symptoms, 2 experiencing severe symptoms, and 30 experiencing non-severe symptoms. Hospitalization was required for 16 patients, and the most common treatments prescribed were sotrovimab and remdesivir. Overall, the study found low mortality rates from COVID-19 infection in patients with B-NHL after bispecific CD20xCD3 therapy. The study also compared the mortality rates of patients who received bispecific antibodies to those treated with CAR-T-cell therapy, finding that bispecific antibody patients had a lower mortality rate. The study concludes that bispecific CD20xCD3 antibodies can be safely prescribed to lymphoma patients who have been vaccinated for COVID-19 with currently circulating virus variants. [Extracted from the article]

Published
2024
Full Text
View/download PDF

28. Hazelnut allergy across Europe dissected molecularly: A EuroPrevall outpatient clinic survey

Author

Datema, Mareen R., Zuidmeer-Jongejan, Laurian, Asero, Riccardo, Barreales, Laura, Belohlavkova, Simona, de Blay, Frédéric, Bures, Peter, Clausen, Michael, Dubakiene, Ruta, Gislason, David, Jedrzejczak-Czechowicz, Monika, Kowalski, Marek L., Knulst, André C., Kralimarkova, Tanya, Le, Thuy-My, Lovegrove, Alison, Marsh, Justin, Papadopoulos, Nikolaos G., Popov, Todor, del Prado, Náyade, Purohit, Ashok, Reese, Gerald, Reig, Isabel, Seneviratne, Suranjith L., Sinaniotis, Athanasios, Versteeg, Serge A., Vieths, Stefan, Zwinderman, Aeilko H., Mills, Clare, Lidholm, Jonas, Hoffmann-Sommergruber, Karin, Fernández-Rivas, Montserrat, Ballmer-Weber, Barbara, and van Ree, Ronald

Published
2015
Full Text
View/download PDF

29. How much is too much? Threshold dose distributions for 5 food allergens

Author

Ballmer-Weber, Barbara K., Fernandez-Rivas, Montserrat, Beyer, Kirsten, Defernez, Marianne, Sperrin, Matthew, Mackie, Alan R., Salt, Louise J., Hourihane, Jonathan O'B., Asero, Riccardo, Belohlavkova, Simona, Kowalski, Marek, de Blay, Frédéric, Papadopoulos, Nikolaos G., Clausen, Michael, Knulst, André C., Roberts, Graham, Popov, Ted, Sprikkelman, Aline B., Dubakiene, Ruta, Vieths, Stefan, van Ree, Ronald, Crevel, René, and Mills, E.N. Clare

Published
2015
Full Text
View/download PDF

30. K2P channel gating mechanisms revealed by structures of TREK-2 and a complex with Prozac

Author

Dong, Yin Yao, Pike, Ashley C. W., Mackenzie, Alexandra, McClenaghan, Conor, Aryal, Prafulla, Dong, Liang, Quigley, Andrew, Grieben, Mariana, Goubin, Solenne, Mukhopadhyay, Shubhashish, Ruda, Gian Filippo, Clausen, Michael V., Cao, Lishuang, Brennan, Paul E., Burgess-Brown, Nicola A., Sansom, Mark S. P., Tucker, Stephen J., and Carpenter, Elisabeth P.

Published
2015

31. Health-related quality of life in food-allergic adults from eight European countries

Author

Goossens, Nicole J., Flokstra-de Blok, Bertine M.J., van der Meulen, Gerbrich N., Arnlind, Marianne H., Asero, Ricardo, Barreales, Laura, Burney, Peter, Cerecedo, Imnaculada, Clausen, Michael, Fernandéz-Rivas, Monteserrat, Frewer, Lynn, de la Hoz Caballer, Belén, Jansson, Sven-Arne, Jedrzejczak-Czechowicz, Monica, Knulst, André C., Kowalski, Marek L., Papadopoulos, Nikos G., Purohit, Ashok, Rokicka, Ewa, Starosta, Pawel, Vásquez-Cortés, Sonia, Duiverman, Eric J., and Dubois, Anthony E.J.

Published
2014
Full Text
View/download PDF

32. Deep learning-based algorithm accurately classifies sleep stages in preadolescent children with sleep-disordered breathing symptoms and age-matched controls.

Author

Somaskandhan, Pranavan, Leppänen, Timo, Terrill, Philip I., Sigurdardottir, Sigridur, Arnardottir, Erna Sif, Ólafsdóttir, Kristín A., Serwatko, Marta, Sigurðardóttir, Sigurveig Þ., Clausen, Michael, Töyräs, Juha, and Korkalainen, Henri

Subjects
SLEEP stages, SLEEP apnea syndromes, PRETEENS, CONVOLUTIONAL neural networks, AGE groups, SPEECH processing systems, SIGNAL convolution
Abstract

Introduction: Visual sleep scoring has several shortcomings, including interscorer inconsistency, which may adversely affect diagnostic decision-making. Although automatic sleep staging in adults has been extensively studied, it is uncertain whether such sophisticated algorithms generalize well to different pediatric age groups due to distinctive EEG characteristics. The preadolescent age group (10-13-year-olds) is relatively understudied, and thus, we aimed to develop an automatic deep learning-based sleep stage classifier specifically targeting this cohort. Methods: A dataset (n = 115) containing polysomnographic recordings of Icelandic preadolescent children with sleep-disordered breathing (SDB) symptoms, and age and sex-matched controls was utilized. We developed a combined convolutional and long short-term memory neural network architecture relying on electroencephalography (F4-M1), electrooculography (E1-M2), and chin electromyography signals. Performance relative to human scoring was further evaluated by analyzing intra- and inter-rater agreements in a subset (n = 10) of data with repeat scoring from two manual scorers. Results: The deep learning-based model achieved an overall cross-validated accuracy of 84.1% (Cohen's kappa κ = 0.78). There was no meaningful performance difference between SDB-symptomatic (n = 53) and control subgroups (n = 52) [83.9% (κ = 0.78) vs. 84.2% (κ = 0.78)]. The inter-rater reliability between manual scorers was 84.6% (κ = 0.78), and the automatic method reached similar agreements with scorers, 83.4% (κ = 0.76) and 82.7% (κ = 0.75). Conclusion: The developed algorithm achieved high classification accuracy and substantial agreements with two manual scorers; the performance metrics compared favorably with typical inter-rater reliability between manual scorers and performance reported in previous studies. These suggest that our algorithm may facilitate less labor-intensive and reliable automatic sleep scoring in preadolescent children. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

33. Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial.

Author

Thieblemont, Catherine, Phillips, Tycel, Ghesquieres, Herve, Cheah, Chan Y., Clausen, Michael Roost, Cunningham, David, Do, Young Rok, Feldman, Tatyana, Gasiorowski, Robin, Jurczak, Wojciech, Kim, Tae Min, Lewis, David John, van der Poel, Marjolein, Poon, Michelle Limei, Cota Stirner, Mariana, Kilavuz, Nurgul, Chiu, Christopher, Chen, Menghui, Sacchi, Mariana, and Elliott, Brian

Published
2023
Full Text
View/download PDF

34. Outcome of limited‐stage peripheral T‐Cell lymphoma after CHOP(−like) therapy: A population based study of 239 patients from the Nordic lymphoma epidemiology group.

Author

Ludvigsen Al‐Mashhadi, Ahmed, Cederleuf, Henrik, Kuhr Jensen, Rasmus, Holm Nielsen, Torsten, Bjerregård Pedersen, Martin, Bech Mortensen, Thomas, Relander, Thomas, Jerkeman, Mats, Ortved Gang, Anne, Kristensen, Anne Louise, Roost Clausen, Michael, de Nully Brown, Peter, Tang Severinsen, Marianne, Jakobsen, Lasse Hjort, Ellin, Fredrik, and El‐Galaly, Tarec Christoffer

Published
2023
Full Text
View/download PDF

35. Work Disability and Return to Work After Lymphoma: A Danish Nationwide Cohort Study.

Author

Maksten, Eva Futtrup, Jakobsen, Lasse Hjort, Kragholm, Kristian Hay, Baech, Joachim, Andersen, Mikkel Porsborg, Madsen, Jakob, Jørgensen, Judit Mészáros, Clausen, Michael Roost, Pedersen, Robert Schou, Dessau-Arp, Andriette, Larsen, Thomas Stauffer, Poulsen, Christian Bjørn, Gang, Anne Ortved, Brown, Peter, Fonager, Kirsten, El-Galaly, Tarec C, and Severinsen, Marianne Tang

Subjects
SICK leave, DISABILITY retirement, LYMPHOMAS, PENSIONS, HODGKIN'S disease, RITUXIMAB
Abstract

Purpose: Many patients diagnosed with lymphoma are of working age. Cancer patients are known to have a higher risk of sick leave and disability pension, but this has only been delineated for certain subtypes of lymphoma. Therefore, this study aimed at investigating the overall risk of disability pension for all lymphoma subtypes and at quantifying return to work for patients with lymphoma in work before diagnosis. Patients and Methods: Patients aged 18– 60 years with lymphoma in complete remission (CR) diagnosed between 2000 and 2019 were included in the study. Using national registers, each patient was matched with five comparators from the general population with same sex, birth year, and level of Charlson Comorbidity Index. Risk of disability pension was calculated from 90 days after CR or end of treatment with competing events (death, retirement pension, early retirement pension, relapse for patients, or lymphoma diagnosis for comparators). Return to work for patients was calculated annually until 5 years after diagnosis for patients employed before diagnosis. Results: In total, 4072 patients and 20,360 comparators were included. There was a significant increased risk of disability pension for patients with all types of lymphoma compared to the general population (5-year risk difference: 5.3 (95% confidence interval (CI): 4.4;6.2)). Patients with non-Hodgkin lymphoma were more likely to get disability pension than patients with Hodgkin lymphoma (sex- and age-adjusted 10-year risk difference: 2.9 (95% CI: 0.3;5.5)). One year after diagnosis, 24.5% of the relapse-free patients were on sick leave. Return to work was highest 2 years after diagnosis (82.1%). Conclusion: Patients with lymphoma across all subtypes have a significantly higher risk of disability pension. Return to work peaks at 2 years after diagnosis. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

38. ION CHANNELS: K2P channel gating mechanisms revealed by structures of TREK-2 and a complex with Prozac

Author

Dong, Yin Yao, Pike, Ashley C.W., Mackenzie, Alexandra, McClenaghan, Conor, Aryal, Prafulla, Dong, Liang, Quigley, Andrew, Grieben, Mariana, Goubin, Solenne, Mukhopadhyay, Shubhashish, Ruda, Gian Filippo, Clausen, Michael V., Cao, Lishuang, Brennan, Paul E., Burgess-Brown, Nicola A., Sansom, Mark S.P., Tucker, Stephen J., and Carpenter, Elisabeth P.

Published
2015
Full Text
View/download PDF

41. Cardiovascular diseases in elderly survivors of diffuse large B-cell lymphoma: a Danish population-based cohort study.

Author

Juul, Maja Bech, Jelicic, Jelena, Anru, Pavithra Laxsen, Engberg, Henriette, Hammershøj Jensen, Pernille, Kristensen, Helene Bjørg, Baech, Joachim, Clausen, Michael Roost, Gang, Anne Ortved, Munksgaard, Lars, El-Galaly, Tarec Christoffer, Frederiksen, Henrik, and Stauffer Larsen, Thomas

Subjects
DIFFUSE large B-cell lymphomas, CARDIOVASCULAR diseases, CORONARY disease, OLDER patients, MYOCARDIAL ischemia, OLDER people
Abstract

Diffuse large B-cell lymphoma is an aggressive disease occurring primarily in elderly patients. Despite high curative rates with doxorubicin-containing treatment, some elderly patients receive less intensive treatments, mainly due to advanced age, comorbidities, and concerns of cardiotoxicity from doxorubicin-containing regimens. We analyzed 1009 patients aged 75 years or older and 10,090 age- and sex-matched comparisons. We aimed to evaluate long-term cardiovascular side effects in elderly patients treated with doxorubicin. Approximately, 64% of patients received doxorubicin-containing treatment. These patients had a persistently increased risk of new-onset heart failure with a hazard ratio of 1.5 and 1.7 when conditioning on survival without heart failure to 6 and 24 months, respectively. Moreover, we observed an increased risk of venous thromboembolism during the first six months following the lymphoma diagnosis. On the contrary, no difference in risk of developing ischemic heart disease or stroke following doxorubicin-containing treatment was observed. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

45. Mental health among patients with non‐Hodgkin lymphoma: A Danish nationwide study of psychotropic drug use in 8750 patients and 43 750 matched comparators.

Author

Øvlisen, Andreas Kiesbye, Jakobsen, Lasse Hjort, Kragholm, Kristian Hay, Nielsen, René Ernst, de Nully Brown, Peter, Dahl‐Sørensen, Rasmus Bo, Frederiksen, Henrik, Mannering, Nikolaj, Josefsson, Pär Lars, Ludvigsen Al‐Mashhadi, Ahmed, Jørgensen, Judit Mészáros, Dessau‐Arp, Andriette, Clausen, Michael Roost, Pedersen, Robert Schou, Torp‐Pedersen, Christian, Severinsen, Marianne Tang, and El‐Galaly, Tarec Christoffer

Published
2022
Full Text
View/download PDF

47. Health sector costs of self-reported food allergy in Europe: a patient-based cost of illness study

Author

Fox, Margaret, Mugford, Miranda, Voordouw, Jantine, Cornelisse-Vermaat, Judith, Antonides, Gerrit, de la Hoz Caballer, Belen, Cerecedo, Inma, Zamora, Javier, Rokicka, Ewa, Jewczak, Maciej, Clark, Allan B., Kowalski, Marek L., Papadopoulos, Nikos, Knulst, Anna C., Seneviratne, Suranjith, Belohlavkova, Simona, Asero, Roberto, de Blay, Frederic, Purohit, Ashok, Clausen, Michael, Flokstra de Blok, Bertine, Dubois, Anthony E., Fernandez-Rivas, Montserrat, Burney, Peter, Frewer, Lynn J., and Mills, Clare E. N.

Published
2013
Full Text
View/download PDF

48. Kiwifruit allergy across Europe: Clinical manifestation and IgE recognition patterns to kiwifruit allergens

Author

Le, Thuy-My, Bublin, Merima, Breiteneder, Heimo, Fernández-Rivas, Montserrat, Asero, Riccardo, Ballmer-Weber, Barbara, Barreales, Laura, Bures, Peter, Belohlavkova, Simona, de Blay, Frédéric, Clausen, Michael, Dubakiene, Ruta, Gislason, David, van Hoffen, Els, Jedrzejczak-Czechowicz, Monika, Kowalski, Marek L., Kralimarkova, Tanya, Lidholm, Jonas, DeWitt, Åsa Marknell, Mills, Clare E.N., Papadopoulos, Nikolaos G., Popov, Todor, Purohit, Ashok, van Ree, Ronald, Seneviratne, Suranjith, Sinaniotis, Athanasios, Summers, Colin, Vázquez-Cortés, Sonia, Vieths, Stefan, Vogel, Lothar, Hoffmann-Sommergruber, Karin, and Knulst, André C.

Published
2013
Full Text
View/download PDF

49. Development and validation of the food allergy severity score.

Author

Fernández‐Rivas, Montserrat, Gómez García, Ismael, Gonzalo‐Fernández, Alejandro, Fuentes Ferrer, Manuel, Dölle‐Bierke, Sabine, Marco‐Martín, Guadalupe, Ballmer‐Weber, Barbara K., Asero, Riccardo, Belohlavkova, Simona, Beyer, Kirsten, de Blay, Frédéric, Clausen, Michael, Datema, Mareen R., Dubakiene, Ruta, Grimshaw, Kate E. C., Hoffmann‐Sommergruber, Karin, Hourihane, Jonathan O'B, Jedrzejczak‐Czechowicz, Monika, Knulst, André C., and Kralimarkova, Tanya

Subjects
FOOD allergy, ALLERGIES, RECEIVER operating characteristic curves, LOGISTIC regression analysis, THERAPEUTICS
Abstract

Background: The heterogeneity and lack of validation of existing severity scores for food allergic reactions limit standardization of case management and research advances. We aimed to develop and validate a severity score for food allergic reactions. Methods: Following a multidisciplinary experts consensus, it was decided to develop a food allergy severity score (FASS) with ordinal (oFASS) and numerical (nFASS) formats. oFASS with 3 and 5 grades were generated through expert consensus, and nFASS by mathematical modeling. Evaluation was performed in the EuroPrevall outpatient clinic cohort (8232 food reactions) by logistic regression with request of emergency care and medications used as outcomes. Discrimination, classification, and calibration were calculated. Bootstrapping internal validation was followed by external validation (logistic regression) in 5 cohorts (3622 food reactions). Correlation of nFASS with the severity classification done by expert allergy clinicians by Best‐Worst Scaling of 32 food reactions was calculated. Results: oFASS and nFASS map consistently, with nFASS having greater granularity. With the outcomes emergency care, adrenaline and critical medical treatment, oFASS and nFASS had a good discrimination (receiver operating characteristic area under the curve [ROC‐AUC]>0.80), classification (sensitivity 0.87–0.92, specificity 0.73–0.78), and calibration. Bootstrapping over ROC‐AUC showed negligible biases (1.0 × 10−6–1.23 × 10−3). In external validation, nFASS performed best with higher ROC‐AUC. nFASS was strongly correlated (R 0.89) to best‐worst scoring of 334 expert clinicians. Conclusion: FASS is a validated and reliable method to measure severity of food allergic reactions. The ordinal and numerical versions that map onto each other are suitable for use by different stakeholders in different settings. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

50. Antibiotic oral provocation challenge in children.

Author

Guðnadóttir, Gyða Katrín, Jónasson, Gunnar, Clausen, Michael, Sørensen, Tonie Gertin, and Kristjánsson, Sigurður

Subjects
DRUG side effects, PROVOCATION tests (Medicine), ANTIBIOTICS, FAMILY history (Medicine), ALLERGIES, ANTIBIOTIC prophylaxis, SKIN tests
Abstract

Aim: The main objective of this study was to see how many of the children, with a suspected antibiotic allergy, developed an allergic or adverse reaction to a drug provocation test. Methods: Data on children that had undergone a drug provocation test for a suspected antibiotic allergy were compiled retrospectively for the period from 2007–2018. The median age at the first provocation was 2.25 years (1.5–5.7). Standardised questionnaires, the children's parents had answered before the provocation, were used to evaluate the originally suspected allergic reaction, previous health, atopic diseases and family history. Results: Ninety‐two (6.4%) of the 1440 children showed a possible mild allergic reaction. Sixty‐four of the 92 children underwent a second drug provocation test 1–2 years later. At that time, only eleven developed a positive‐ or a possible‐delayed reaction. Conclusion: An immediate moderate or severe allergic reaction was excluded in all cases of suspected antibiotic allergy in this study. Our study indicates that an oral drug provocation test is safe. It may be appropriate to wait for 6 months or more after the initial event of ADR before these tests are performed. A second oral provocation 1–2 years after the first one shows that ADRs are outgrown in most children. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results